Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Tarsus expands eye care empire with $800m Alkeus buy
CompaniesTarsus PharmaceuticalsAlkeus PharmaceuticalsDiseasesretinal diseaserare eye disorders
FDA approves Moderna’s flu shot in first for mRNA vaccines
CompaniesModernaAssetsModerna's flu shotDiseasesinfluenza
Spain continued to lead the EU in clinical trials in 2025, AEMPS reports
Diseasesoncologyrare diseases
Medicare’s GLP-1 Bridge program redraws the weight management pricing map
In perfect harmony: Jazz tunes up epilepsy portfolio with $820m Actio deal
CompaniesJazz PharmaceuticalsActio BiosciencesAssetsABS-1230ABS-0871DiseasesKCNT1+ epilepsyCharcot-Marie-Tooth disease type 2C
Epicrispr raises $90m to advance muscular dystrophy therapy
CompaniesEpicrisprAssetsepigenetic therapy for facioscapulohumeral muscular dystrophyDiseasesfacioscapulohumeral muscular dystrophy
Innate Pharma lands $580m Sobi partnership for lymphoma therapy
CompaniesInnate PharmaSobiAssetslacutamabDiseasescutaneous T-cell lymphomaSézary syndromemycosis fungoides
CMS, HRSA target 340B with new payment, rebate rules
DOJ adopts targeted approach to mergers
CompaniesReed SmithDOJ
Biopharma large and small name new legal chiefs
CompaniesaTyr PharmaBiogenCity TherapeuticsCytomX TherapeuticsSanofi
340B rebate model pilot on tap; 340B drug pricing proposed changes, and potential DTC changes on the horizon
Regulatory uncertainty stalls AI adoption by sponsors, CROs
Poolbeg CEO delves inside the UK’s record $2.84bn fundraising quarter
CompaniesPoolbeg PharmaIsomorphic Labs
Vaderis secures $152m to advance rare disease treatment
CompaniesVaderis TherapeuticsAssetsengasertibDiseaseshereditary hemorrhagic telangiectasia
Medable’s AI agent delivers $21m per program, 82x ROI, Tufts study shows
CompaniesMedable Inc.Tufts Center for the Study of Drug Development
Researchers call for EMT training to support mobile staff in decentralized trials
Making more than chocolate: Swiss CDMO gets go-ahead to make siRNAs
Companiesten23 healthAssetssiRNAsmRNAantisense oligonucleotides
AbCellera taps capital markets for $200m to bankroll menopause antibody
CompaniesAbCellera BiologicsAssetsABCL635Diseasesmenopause